Sanofi SA's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 69/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 61.88.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanofi SA's Score
Industry at a Glance
Industry Ranking
69 / 159
Overall Ranking
176 / 4592
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
61.882
Target Price
+27.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sanofi SA Highlights
StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 11.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 251.34M shares, decreasing 9.80% quarter-over-quarter.
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Ticker SymbolSNY
CompanySanofi SA
CEOHudson (Paul)
Websitehttps://www.sanofi.com/
FAQs
What is the current price of Sanofi SA (SNY)?
The current price of Sanofi SA (SNY) is 48.680.
What is the symbol of Sanofi SA?
The ticker symbol of Sanofi SA is SNY.
What is the 52-week high of Sanofi SA?
The 52-week high of Sanofi SA is 60.115.
What is the 52-week low of Sanofi SA?
The 52-week low of Sanofi SA is 44.617.
What is the market capitalization of Sanofi SA?
The market capitalization of Sanofi SA is 118.50B.
What is the net income of Sanofi SA?
The net income of Sanofi SA is 6.01B.
Is Sanofi SA (SNY) currently rated as Buy, Hold, or Sell?
According to analysts, Sanofi SA (SNY) has an overall rating of Buy, with a price target of 61.882.
What is the Earnings Per Share (EPS TTM) of Sanofi SA (SNY)?
The Earnings Per Share (EPS TTM) of Sanofi SA (SNY) is 4.133.